Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$7.53 -3.1%	$8.02	$6.85 ▼ $21.01	$458.54M	-0.08	497,182 shs	221,414 shs
MBX MBX Biosciences	$11.75 -3.6%	$11.79	$4.81 ▼ $27.50	$392.73M	N/A	264,355 shs	273,419 shs
SKYE Skye Bioscience	$3.89 +4.6%	$2.95	$1.14 ▼ $7.47	$115.22M	1.95	511,805 shs	320,616 shs
TERN Terns Pharmaceuticals	$5.64 +0.7%	$3.83	$1.87 ▼ $11.40	$489.09M	-0.11	1.46 million shs	1.33 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	+1.30%	-0.89%	-6.61%	-1.52%	-58.02%
MBX MBX Biosciences	-1.93%	-1.69%	+20.69%	+59.97%	+1,218,999,900.00%
SKYE Skye Bioscience	+0.81%	-5.58%	+79.28%	+159.23%	-41.05%
TERN Terns Pharmaceuticals	+6.26%	+14.99%	+43.59%	+132.85%	-41.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	1.7546 of 5 stars	3.5	0.0	0.0	2.2	1.7	0.6
MBX MBX Biosciences	2.3633 of 5 stars	3.5	0.0	0.0	2.5	1.7	0.6
SKYE Skye Bioscience	2.2416 of 5 stars	3.5	4.0	0.0	2.7	0.0	0.0
TERN Terns Pharmaceuticals	3.8724 of 5 stars	3.3	1.0	4.1	2.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$30.00	298.41% Upside
MBX MBX Biosciences	3.00	Buy	$37.57	219.76% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	326.74% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	177.04% Upside

Current Analyst Ratings Breakdown

Latest SKYE, MBX, TERN, and CGEM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/13/2025	TERN Terns Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $15.00
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
4/21/2025	TERN Terns Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.14 per share	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$167.38M	-$2.91	N/A	N/A	N/A	N/A	-29.47%	-28.19%	8/6/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	-$26.57M	-$0.82	N/A	N/A	N/A	N/A	-53.92%	-48.58%	N/A
TERN Terns Pharmaceuticals	-$88.85M	-$1.09	N/A	N/A	N/A	N/A	-28.81%	-27.55%	8/4/2025 (Estimated)

Latest SKYE, MBX, TERN, and CGEM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.7951	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.29	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	11.62	11.62
MBX MBX Biosciences	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	11.85	11.85
TERN Terns Pharmaceuticals	N/A	30.89	30.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
MBX MBX Biosciences	N/A
SKYE Skye Bioscience	21.09%
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
MBX MBX Biosciences	52.19%
SKYE Skye Bioscience	4.50%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.01 million	54.79 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A
SKYE Skye Bioscience	11	30.98 million	29.58 million	Optionable
TERN Terns Pharmaceuticals	40	87.34 million	86.03 million	Not Optionable

SKYE, MBX, TERN, and CGEM Headlines

Recent News About These Companies

Obesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-Waiting

July 14, 2025 | biospace.comB

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $15.63 Average Price Target from Analysts

July 12, 2025 | americanbankingnews.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 9, 2025 | marketbeat.com

Terns Pharmaceuticals CEO & Director Acquires 98% More Stock

July 4, 2025 | finance.yahoo.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Purchases $39,300.00 in Stock

June 30, 2025 | marketbeat.com

Terns pharmaceuticals CEO Burroughs buys $90k in shares

June 27, 2025 | investing.com

Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

June 26, 2025 | fiercebiotech.comF

Insider Buying: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Buys 23,314 Shares of Stock

June 25, 2025 | marketbeat.com

Terns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - Nasdaq

June 24, 2025 | nasdaq.com

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - Morningstar

June 24, 2025 | morningstar.comM

Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

June 23, 2025 | medpagetoday.comM

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

June 23, 2025 | globenewswire.com

Population-Level Weight Loss Seen With Primary Care Protocol

June 21, 2025 | medscape.comM

SG Americas Securities LLC Purchases 380,489 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

June 18, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Buys $19,750.00 in Stock

June 17, 2025 | insidertrades.com

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies | DelveInsight

June 13, 2025 | theglobeandmail.com

3 Penny Stocks Wall Street Sees With 243% Upside

June 11, 2025 | 247wallst.com

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 29, 2025 | globenewswire.com

Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential

May 27, 2025 | investing.com

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 14, 2025 | globenewswire.com

Why Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 11.67%

May 10, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
D-Wave Goes International With South Korea Partnership
By Nathan Reiff | June 23, 2025
View D-Wave Goes International With South Korea Partnership
3 Summer Short-Squeeze Candidates With Catalysts for Covering
By Thomas Hughes | June 30, 2025
View 3 Summer Short-Squeeze Candidates With Catalysts for Covering

SKYE, MBX, TERN, and CGEM Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$7.53 -0.24 (-3.09%)

Closing price 04:00 PM Eastern

Extended Trading

$7.52 0.00 (-0.07%)

As of 04:20 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

MBX Biosciences NYSE:MBX

$11.75 -0.44 (-3.61%)

Closing price 04:00 PM Eastern

Extended Trading

$11.73 -0.02 (-0.17%)

As of 04:04 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Skye Bioscience NASDAQ:SKYE

$3.89 +0.17 (+4.57%)

Closing price 04:00 PM Eastern

Extended Trading

$3.92 +0.03 (+0.77%)

As of 07:46 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Terns Pharmaceuticals NASDAQ:TERN

$5.64 +0.04 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$5.60 -0.03 (-0.62%)

As of 06:00 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time